RecruitingNot applicableNCT05726825

Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock

Studying Antisynthetase syndrome

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hannover Medical School
Principal Investigator: Sascha David, Prof. Dr.
University of Zurich
Intervention: Therapeutic Plasma Exchange (TPE)(device)
Enrollment: 274 enrolled
Eligibility: 18-80 years · All sexes
Timeline: 2025 – 2028

Study locations (25)

University Hospital Innsbruck, Innsbruck, Austria
University Hospital Vienna, Vienna, Austria
St. Joseph Hospital, Berlin, Germany
University Hospital Berlin Charite, Berlin, Germany
University Hospital Bonn, Bonn, Germany
Hospital Braunschweig, Braunschweig, Germany
Hospital Bremerhaven, Bremerhaven, Germany
Hospital Cologne Meerheim, Cologne, Germany
University Hospital Cologne, Cologne, Germany
University Hospital Erlangen, Erlangen, Germany
University Hospital Essen, Essen, Germany
University Hospital Halle, Halle, Germany
University Hospital Hamburg (UKE), Hamburg, Germany
Hannover Medical School Anesthesiology, Hanover, Germany
Hannover Medical School Internal Medicine, Hanover, Germany
+10 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05726825 on ClinicalTrials.gov

Other trials for Antisynthetase syndrome

Additional recruiting or active studies for the same condition.

See all trials for Antisynthetase syndrome →

← Back to all trials